Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center
Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung
squamous cell carcinoma has a better tumor response rate and safety, therefore, this program
is applied to neoadjuvant therapy, may obtain better tumor pathological remission rate,
improve the operation resection rate, thus improve the prognosis.The main purpose of this
study is to observe the safety and efficacy of albumin-bound paclitaxel / carboplatin in the
treatment of lung squamous cell carcinoma of stage IIB and IIIA.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor ORR and Number of Adverse Events
From date of randomization until the date of progression, assessed up to 2 months
Yes
jianxing he, MD
Principal Investigator
The First Affiliated Hospital of Guangzhou Medical University
United States: Food and Drug Administration
FAH20120906
NCT01872403
October 2012
December 2017
Name | Location |
---|